<DOC>
	<DOCNO>NCT01029405</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AN2728 Ointment B , 2.0 % 0.5 % , compare Ointment Vehicle B , apply twice daily 12 week , treatment plaque type psoriasis</brief_summary>
	<brief_title>Safety Efficacy Study Novel Ointment Treat Plaque Type Psoriasis</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , vehicle-controlled , bilateral design . Patients apply test article AN2728 Ointment B ( 0.5 % 2 % ) , Ointment B Vehicle twice daily 12 week . The assigned study medication apply two comparable treatment target plaque identify baseline . One test article apply one plaque test article anatomically distinct plaque . All efficacy evaluation measure two plaque identify baseline visit .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female &gt; 18 year age time enrollment Clinical diagnosis stable plaque type psoriasis Two target plaque similar severity meeting follow criterion : 5 cm2 â‰¤ 100 cm2 , compute multiply great diameter plaque diameter plaque perpendicular great diameter Bilaterally locate ( right/left ) plaques arm plaque locate trunk . Plaques locate trunk must separate least 10 cm Overall target plaque severity score ( OTPSS ) 24 ( mild moderate ) 1 point difference score two target plaque Willing able apply study drug direct , comply study instruction commit followup visit Ability understand , agree sign study Informed Consent Form ( ICF ) prior initiation protocol related procedure Any dermatological condition , disease state physical condition could interfere clinical evaluation might expose patient unacceptable risk study participation Any underlying disease ( ) dermatological condition require use exclusionary topical systemic therapy ( see ) Clinically significant , abnormal Screening laboratory result ( unless approve medical monitor ) Known sensitivity component study medication Spontaneously improve rapidly deteriorate psoriatic plaque pustular/exfoliative , guttate , erythrodermic nonplaque form psoriasis Concomitant use topical systemic therapy might alter course psoriasis Females child bear potential . Females must postmenopausal ( base FSH level ) surgically sterile ( hysterectomy bilateral oophorectomy ) Washout period exclusionary therapy : Oral retinoids : 8 week Nonretinoid systemic drug might alter course psoriasis : 4 week Psoralens UVA ( PUVA ) : 4 week UltravioletB ( UVB ) therapy : 4 week Topical drug might alter course psoriasis : 2 week Use emollients/moisturizers area ( ) treat : 2 day prior Baseline visit AIDS AIDSrelated illness Concurrent participation another drug device research study within 30 day prior enrollment Use lithium hydroxychloroquinecontaining product ( e.g. , Plaquenil ) Use betablocking medication ( e.g. , Propranolol ) dose stabilize least 3 month Use AN2728 previous clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Topical</keyword>
	<keyword>Plaque type psoriasis</keyword>
</DOC>